American Industrial Partners Strikes $1.27bn Acquisition of Avanos Medical
American Industrial Partners (AIP) has agreed to acquire Avanos Medical in a take-private transaction valued at roughly $1.27bn, with the deal announced on Tuesday, according to Private Equity Wire. The agreement reflects AIP’s focus on scaling healthcare platforms with differentiated product portfolios, and it prompted a sharp rally in Avanos shares, climbing by close to 68% in premarket trading.
Avanos Medical’s Operations and Key Products
Avanos Medical, headquartered in Alpharetta, Georgia, specializes in medical devices for chronic pain treatment without opioids, as well as clinical nutrition solutions including enteral feeding systems for patients unable to eat independently, according to Private Equity Wire. Central to AIP’s investment thesis is Coolief, Avanos’ lead product, which uses minimally invasive radiofrequency technology to interrupt pain signals by targeting specific nerves, positioning the company within the growing non-opioid pain management segment.
Competitive Landscape for Avanos
Avanos operates in a competitive landscape, facing established medtech players such as Stryker, Medtronic, and Boston Scientific, all of which offer competing ablation-based solutions within broader device portfolios, according to Private Equity Wire. This environment highlights the challenges and opportunities in the medical device sector for firms like Avanos.
Transaction Details and Timeline
Under the terms of the deal, Avanos shareholders will receive $25 per share in cash, representing a premium of approximately 72% to the company’s last closing price. The transaction is expected to close in the second half of 2026, subject to customary approvals and conditions, as noted in the report by Reuters via Private Equity Wire.
